Described here are delivery devices for delivering one or more implants to the body, and methods of using. The delivery devices may deliver implants to a variety of locations within the body, for a number of different uses. In some variations, the delivery devices have a cannula with one or more curved sections. In some variations, a pusher may be used to release one or more implants from the cannula. In some variations, one or more of the released implants may be a self-expanding device. Methods of delivering implants to one or more sinus cavities are also described here.

Described here are delivery devices for delivering one or more implants to the body, and methods of using. The delivery devices may deliver implants to a variety of locations within the body, for a number of different uses. In some variations, the delivery devices have a cannula with one or more curved sections. In some variations, a pusher may be used to release one or more implants from the cannula. In some variations, one or more of the released implants may be a self-expanding device. Methods of delivering implants to one or more sinus cavities are also described here.

The invention relates to developing a novel water and capsule formulation using fenofibrate which is difficult to dissolve and control its release rate in vitro. For example, the invention relates to the creation of capsules and wafers comprising: fenofibrate, a surfactant, a carrier wax, a film former, a plasticizer, and optionally a super disintegrant or other ingredients. The invention further relates to the process of forming such capsules and wafers.

Provided herein are glycosylated peptide amphiphiles (GPAs), supramolecular glyconanostructures assembled therefrom, and methods of use thereof. In particular, provided herein are glycosaminoglycan (GAG) mimetic peptide amphiphiles (PAs) and supramolecular GAG mimetic nanostructures assembled therefrom that mimic the biological activities of GAGs, such as heparin, heparan sulfate, hyaluronic acid etc.

Provided herein are glycosylated peptide amphiphiles (GPAs), supramolecular glyconanostructures assembled therefrom, and methods of use thereof. In particular, provided herein are glycosaminoglycan (GAG) mimetic peptide amphiphiles (PAs) and supramolecular GAG mimetic nanostructures assembled therefrom that mimic the biological activities of GAGs, such as heparin, heparan sulfate, hyaluronic acid etc.

The present disclosure provides crystalline forms of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine (A2-73), in freebase or salt forms. Also described are pharmaceutical formulations and dosage forms comprising the disclosed crystal forms, and methods of using crystalline A2-73 in dosage forms for neuroprotection including treatment of neurodegenerative and other diseases.

The present invention relates to transdermal devices comprising prodrugs of anti-pyretic, analgesic, or anti-inflammatory molecules, methods of making such devices, and methods of use thereof for treating, preventing, minimizing, and/or diminishing fever or pain.

A product for oral delivery of nicotine comprising a powder composition of a nicotine source, at least one pH adjusting agent, and at least one filler, contained in a pouch which is permeable to saliva and to components of the powder composition once dissolved in saliva, wherein the composition has a solubility of less than 5 g/100 ml. The invention also relates to a method for preparing said product and also the use of said product.

Presented herein are compositions and methods for generating stem cell derived retinal tissue and isolated retinal progenitor cells for use in the treatment of retinal degenerative diseases and disorders.

An external skin preparation comprises the following components (A) to (E), wherein the mass ratio of the component (A) to the component (B), (A)/(B), is from 0.3 to 2.0, wherein the content of the component (C) is from 0.1 to 1 mass %, and wherein the preparation has a pH at 25° C. of from 4.0 to 7.0: (A) one or more selected from the group consisting of aliphatic alcohols having from 14 to 20 carbon atoms; (B) two or more selected from the group consisting of polyhydric alcohol fatty acid ester-type nonionic surfactants; (C) one or more selected from the group consisting of N-acyl amino acids, N-acyl taurine, salts thereof, and phospholipids; (D) one or more selected from the group consisting of steroidal anti-inflammatory drugs, non-steroidal anti-inflammatory drugs, and heparinoids; and (E) water.